Anika Therapeutics ANIK Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Anika Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The official record: Anika Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Anika Therapeutics's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Anika Therapeutics's cash & equivalents?
- Anika Therapeutics (ANIK) reported cash & equivalents of $41.02M in Q1 2026.
- How has Anika Therapeutics's cash & equivalents changed year-over-year?
- Anika Therapeutics's cash & equivalents decreased by 23.1% year-over-year, from $53.37M to $41.02M.
- What is the long-term trend for Anika Therapeutics's cash & equivalents?
- Over 5 years (2020 to 2025), Anika Therapeutics's cash & equivalents has grown at a -9.7% compound annual growth rate (CAGR), from $95.82M to $57.48M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.